Advanced Search

 

Study ID Status Title Patient Level Data
201624 Completed PGx7571: Pharmacogenetic Evaluation of FCGR Variation in patients treated with ofatumumab in study OMB115991
201625 Completed PGx7602: Pharmacogenetic Evaluation of FCGR Variation in patients treated with ofatumumab in study OMB110927
201627 Completed PGx7604: Pharmacogenetic Evaluation of FCGR Variation in patients treated with ofatumumab in study OMB114242
201630 Recruiting Long term hepatitis A virus (HAV) antibody persistence in children vaccinated with 1 dose and those vaccinated with 2 doses of Havrix® in Panama
201634 Completed PGx7575: Pharmacogenetic Evaluation of FCGR Variation in patients treated with ofatumumab in study OMB110928
201636 Active, Not Recruiting A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed (SWORD-1)
201637 Active, Not Recruiting A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults who are Virologically Suppressed (SWORD-2)
201641 Active, Not Recruiting HO-14-14607 - OBSERVATIONAL STUDY TO EXPLORE THE SAFETY, COSTS AND HEALTH CARE RESOURCE UTILIZATION, ASSOCIATED WITH FIRST LINE ARZERRA (OFATUMUMAB) OR GAZYVA (OBINUTUZUMAB) THERAPIES IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REAL WORLD SETTING
201657 Completed Meta-analysis of clinical efficacy studies of licensed Rheumatoid Arthritis (RA) treatments
201659 Terminated An Adaptive Design Open Label Pilot Study in Rheumatoid Arthritis Patients to Assess Inflammation Using Molecular Imaging Techniques
201661 Completed Skin Residency Study of Topically Applied GSK2894512 Cream in Healthy Volunteers
201664 Recruiting A three-part open-label, non-randomised, dose-escalation study to investigate the safety and tolerability of GSK3039294 administered as a single dose to healthy volunteers, and as repeat dose to healthy volunteers and patients with systemic amyloidosis
201670 Completed Indirect Comparison of Albiglutide and Exenatide QW using the Bucher method
201672 Withdrawn A Phase I, Open-Label, Dose-Finding Study of Afuresertib Administered in Combination with either Enzalutamide (Xtandi) or Abiraterone (Zytiga) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
201673 Not yet recruiting Impact of early versus late co-administration of Advair in patients treated with tiotropium for the management of COPD in Quebec
201674 Completed A Phase I, 2-part relative oral bioavailability study of different fixed dose combinations of dolutegravir and rilpivirine in fasted and fed healthy subjects
201677 Recruiting A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
201681 Completed An open-label balanced, randomised, single dose, two-way crossover study to determine the bioequivalence of GW483100 10 mg tablets (containing montelukast sodium equivalent to 10 mg of montelukast) relative to reference montelukast sodium 10 mg tablets (containing montelukast sodium equivalent to 10 mg of montelukast) in healthy male and female volunteers under fasting conditions
201682 Completed A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with acute, uncomplicated influenza (201682)
201691 Completed A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban
201703 Completed The Utility of a Clinical Questionnaire to Identify Subjects with Features of Both Asthma and COPD
201709 Recruiting ECHO Analyses From Randomized Controlled Trials of Dabrafenib to Evaluate the Potential for Cardiac Valve Abnormalities
201710 Recruiting Evaluation of Secondary Malignancies in Patients Treated with Dabrafenib in Randomized, Controlled Trials
201711 Recruiting Evaluating Cardiomyopathy and Retinal Pigmented Epithelial Detachments (RPED) in Subjects Treated with GSK1120212 (MEKINIST) as Monotherapy or in Combination with Other Anticancer Therapies
201712 Recruiting Evaluating Cardiomyopathy and Retinal Pigmented Epithelial Detachments (RPED) in Subjects Treated with GSK1120212 (MEKINIST) as Monotherapy or in Combination with Other Anticancer Therapies

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.